< Back to portfolio

Medicago was a public biotechnology company based in Quebec City, Canada. The company specialized in plant-based production of vaccines and therapeutic proteins. Utilizing live plant leaves as bioreactors, Medicago developed virus-like particles for rapid vaccine development. In 2013, Medicago was acquired by Mitsubishi Tanabe Pharma for $360M USD.

Specialty

Vaccine platform

Fund name

CTI LSF I

Position

Syndicate

Board

n/a

Investment Date

April 4, 2011

Exit Detail

Medicago acquired by Mitsubishi Tanabe Pharma for $360M USD

Initial Series Round

PIPE

Investment Thesis

Medicago’s plant-based platform had significant speed and cost advantages compared to traditional protein and vaccine production methods

Related News

September 27, 2011

Medicago Completes $25 Million Private Placement

Read

April 5, 2011

Medicago Announces Closing of C$17.4 Million Equity Offering

Read

July 12, 2013

Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

Read
More News